A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
NCT00219063 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 844
Last updated 2017-05-17
Summary
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
Conditions
Interventions
- DRUG
-
aliskiren
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-02-28
- Primary Completion
- 2006-03-31
- Completion
- 2006-03-31
Countries
- United States
Study Locations
More Related Trials
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
NCT00260923 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
NCT00219128 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
NCT00219076 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure
NCT00219180 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure
NCT00219167 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.
NCT00219024 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00765947 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
NCT00368277 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension
NCT00262236 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
NCT00219037 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
NCT00797862 ·Status: COMPLETED ·Phase: PHASE3
-
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
NCT00402103 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
NCT00631917 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
NCT00219089 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients
NCT00219193 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
NCT00219141 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01113047 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
NCT00343551 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
NCT00219102 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
NCT00927394 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00654875 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
NCT00739973 ·Status: COMPLETED ·Phase: PHASE3
-
Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population
NCT00760266 ·Status: COMPLETED ·Phase: PHASE4
-
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
NCT01151410 ·Status: COMPLETED ·Phase: PHASE3
-
Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension
NCT00942994 ·Status: COMPLETED ·Phase: PHASE4